Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Concurrent Use of 5% Natamycin and 2% Econazole for the Management of Fungal Keratitis

Prajna, N Venkatesh DNB; Nirmalan, Praveen K MPH; Mahalakshmi, Rajendran MSC; Lalitha, Prajna MD; Srinivasan, Muthiah MS

doi: 10.1097/01.ico.0000134193.64357.82
Clinical Sciences

Purpose: To determine if concurrent use of 5% natamycin and 2% econazole offers greater benefits than monotherapy with 5% natamycin for the management of fungal keratitis.

Methods: Subjects presenting to the cornea service were treated with 5% natamycin and 2% econazole used concurrently. We compared the results with a historical control of patients treated with 5% natamycin in the same calendar year. The same clinical and examination protocol including inclusion and exclusion criteria was used for both groups.

Results: We compared results of 47 subjects on concurrent use of 5% natamycin and 2% econazole with all 53 subjects who had received 5% natamycin in a previous study (historical controls). Baseline characteristics were similar between the 2 groups. There were no significant differences (P = 0.9) between the 2 arms for success (defined as a healed or healing ulcer).

Conclusions: Concurrent use of 5% natamycin and 2% econazole does not appear to offer additional benefits over monotherapy with 5% natamycin for the management of fungal keratitis.

From the Aravind Medical Research Foundation, Aravind Eye Care System, Madurai, India.

Received for publication November 21, 2003; accepted May 9, 2004.

The study was supported by the Aravind Medical Research Foundation, Madurai.

The authors have no financial interest in the matters discussed.

Reprints: N. V. Prajna, Cornea Service, Aravind Eye Care System, 1, Anna Nagar, Madurai-625020, India (e-mail: prajna@aravind.org).

© 2004 Lippincott Williams & Wilkins, Inc.